Cited by

• Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma.

  Holloway PA, Kaldenhoven N, Kok-Schoemaker HM, Van Kessel B, Van Blokland WT, Bloem AC, Lokhorst HM. Holloway PA, et al. Clin Exp Immunol. 2003 Feb;131(2):340-6. doi: 10.1046/j.1365-2249.2003.02067.x. Clin Exp Immunol. 2003. PMID: 12562398 Free PMC article.
• The Emerging Landscape of Immune Cell Therapies.

  Weber EW, Maus MV, Mackall CL. Weber EW, et al. Cell. 2020 Apr 2;181(1):46-62. doi: 10.1016/j.cell.2020.03.001. Cell. 2020. PMID: 32243795 Free PMC article. Review.
• Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

  Deol A, Lum LG. Deol A, et al. Cancer Treat Rev. 2010 Nov;36(7):528-38. doi: 10.1016/j.ctrv.2010.03.004. Epub 2010 Apr 9. Cancer Treat Rev. 2010. PMID: 20381970 Free PMC article. Review.
• Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT.

  Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NP, Finke J, Robin M, Fedele R, Bron D, Yakoub-Agha I, van Biezen A, de Witte T, Kröger N, Olavarria E; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Chalandon Y, et al. Haematologica. 2014 Sep;99(9):1492-8. doi: 10.3324/haematol.2013.100198. Epub 2014 Jul 4. Haematologica. 2014. PMID: 24997146 Free PMC article.
• BCR-ABL1 transcripts (MR^4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia.

  Lee SE, Choi SY, Kim SH, Song HY, Yoo HL, Lee MY, Kang KH, Hwang HJ, Jang EJ, Kim DW. Lee SE, et al. Korean J Intern Med. 2017 Jan;32(1):125-136. doi: 10.3904/kjim.2015.187. Epub 2016 Jun 22. Korean J Intern Med. 2017. PMID: 27334764 Free PMC article.